Datasheet | Reviews | Related Products | Protocols |
Recombinant Human VEGF / VEGFA / VEGF165 protein (Catalog#11066-HNAB) | |
105 | |
Rabbit IgG | |
0.2 μm filtered solution in PBS | |
This antibody was obtained from a rabbit immunized with purified, recombinant Human VEGF / VEGFA / VEGF165 (rh VEGF / VEGFA / VEGF165; Catalog#11066-HNAB; P15692-4; Met 1-Arg 191). |
Reactivity: Human Application: ELISA |
Reactivity: Human Application: ELISA |
Reactivity: Human Application: ELISA |
Reactivity: Human Application: ELISA |
Reactivity: Human Application: WB IP |
Reactivity: Human Application: ELISA WB IHC-P |
Reactivity: Human Application: |
Reactivity: Human Application: ELISA |
Reactivity: Human Application: B/N |
Reactivity: Human Application: ELISA |
Reactivity: Human Application: B/N |
Reactivity: Human Application: ELISA |
Reactivity: Mouse Application: ELISA |
Reactivity: Mouse Application: ELISA |
Reactivity: Rat Application: ELISA |
Reactivity: Rat Application: ELISA |
Reactivity: Rat Application: |
Reactivity: Rat Application: ELISA |
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.
Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
Product name | Product name |
Availability |